December 13, 2010 -- Genovis provides novel technical solutions for Imaging and Antibody Engineering. The objectives are to maintain a strong, collaborative and innovative product portfolio for customers in the pharmaceutical industry and in the academic research community.
Sarah Fredriksson, Chief Executive Officer of Genovis, said “We are excited to have the opportunity to bring ADVANSYS into our distribution network and it will allow us to reach a large number of customers in Israeli and we are looking forward to working with the experienced team in Advansys”
ADVANSYS is a young and dynamic Company, established by professionals with long term experience in the promotion of advanced technologies to researchers and other professionals in the Life Sciences, Biotechnology and Biomedical industry. The primary goal of ADVANSYS is to supply the Israeli life science and biomedical market with the latest innovations in gene, protein and cell analysis. ADVANSYS is committed to provide continuous support to customers in all stages of application development, excellent technical support and after-sales service.
“ADVANSYS is striving to present state-of-the-art technologies and high quality products to its customers. We are excited to enter a collaboration with such an innovative company as Genovis AB and look forward to start promoting its unique product offering in the highly advanced and promising life sciences market in Israel.” said Dr. Eleni Bantinaki, Director and Founder of ADVANSYS Technologies of Life Ltd.
Find out more, contact: Sarah Fredriksson, CEO, Genovis AB Tel: +46 46 10 12 35 sarah.fredriksson@genovis.com Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company’s patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified adviser.
